Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The T-helper 1 (TH1) immune reaction is essential for the eradication of hepatitis C virus (HCV) during pegylated interferon α (PEG-IFN-α)- and ribavirin (RBV)-based therapy in chronic HCV patients. Secreted phosphoprotein 1 (SPP1) was shown to be a crucial cytokine for the initiation of a TH1 immune response. We aimed to investigate whether SPP1 single nucleotide polymorphisms (SNPs) may influence sustained virological response (SVR) rates. Methods: Two SNPs in the promoter region of SPP1 at the –443 C>T and –1748 G>A loci were genotyped in 100 patients with chronic HCV genotype 4 infection using a TaqMan SNP genotyping assay. Results: Sixty-seven patients achieved a SVR, and 33 patients showed no SVR. Patients carrying the T/T genotype at the –443 locus showed a significantly higher SVR rate than those carrying the C/T or C/C genotype (83.67% vs 50.98%, p<0.001). At the –1748 locus, the SVR rate was significantly higher in patients with the G/G genotype than in those with the A/A genotype (88.89% vs 52.63%, p=0.028) and in patients with the G/A genotype than in those with the A/A genotype (85.29% vs 52.63%, p=0.001). Conclusions: SPP1 SNPs at –443 C>T and –1748 G>A loci may be useful markers for predicting the response to PEG-IFN-α-2b plus RBV therapy in Egyptian patients with chronic HCV genotype 4 infection.
Abstract
Background/Aims: The T-helper 1 (TH1) immune reaction is essential for the eradication of hepatitis C virus (HCV) during pegylated interferon α (PEG-IFN-α)- and ribavirin (RBV)-based therapy in chronic HCV patients. Secreted phosphoprotein 1 (SPP1) was shown to be a crucial cytokine for the initiation of a TH1 immune response. We aimed to investigate whether SPP1 single nucleotide polymorphisms (SNPs) may influence sustained virological response (SVR) rates. Methods: Two SNPs in the promoter region of SPP1 at the –443 C>T and –1748 G>A loci were genotyped in 100 patients with chronic HCV genotype 4 infection using a TaqMan SNP genotyping assay. Results: Sixty-seven patients achieved a SVR, and 33 patients showed no SVR. Patients carrying the T/T genotype at the –443 locus showed a significantly higher SVR rate than those carrying the C/T or C/C genotype (83.67% vs 50.98%, p<0.001). At the –1748 locus, the SVR rate was significantly higher in patients with the G/G genotype than in those with the A/A genotype (88.89% vs 52.63%, p=0.028) and in patients with the G/A genotype than in those with the A/A genotype (85.29% vs 52.63%, p=0.001). Conclusions: SPP1 SNPs at –443 C>T and –1748 G>A loci may be useful markers for predicting the response to PEG-IFN-α-2b plus RBV therapy in Egyptian patients with chronic HCV genotype 4 infection.
참고문헌 (33)
- "Hepatitis C fact sheet, No. 164" (2011)[URL]
- Te HS, "Epidemiology of hepatitis B and C viruses: a global overview", Clin Liver Dis, 14, pp.1~21 (2010)
- Khattab MA, "Management of hepatitis C virus genotype 4: recommendations of an international expert panel", J Hepatol, 54, pp.1250~1262 (2011)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Backus LI, "A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C", Clin Gastroenterol Hepatol, 9, pp.509~516 (2011)
- Kau A, "Treatment predictors of a sustained virologic response in hepatitis B and C", J Hepatol, 49, pp.634~651 (2008)
- Hnatyszyn HJ, "Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes", Antivir Ther, 10, pp.1~11 (2005)
- Berg T, "Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy", Hepatology, 37, pp.600~609 (2003)
- Zeuzem S, "Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a", Gastroenterology, 120, pp.1438~1447 (2001)
- Sodek J, "Osteopontin", Crit Rev Oral Biol Med, 11, pp.279~303 (2000)
- Chabas D, "Osteopontin, a multi-faceted molecule", Med Sci, 21, pp.832~838 (2005)
- Renkl AC, "Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype", Blood, 106, pp.946~955 (2005)
- Ashkar S, "Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity", Science, 287, pp.860~864 (2000)
- Young MF, "cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN)", Genomics, 7, pp.491~502 (1990)
- Giacopelli F, "Polymorphisms in the osteopontin promoter affect its transcriptional activity", Physiol Genomics, 20, pp.87~96 (2004)
- Hummelshoj T, "A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression", Mol Immunol, 43, pp.980~986 (2006)
- Thursz M, "Understanding the host genetics of chronic hepatitis B and C", Semin Liver Dis, 31, pp.115~127 (2011)
- Mochida S, "Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients", Biochem Biophys Res Commun, 313, pp.1079~1085 (2004)
- Naito M, "SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C", J Gastroenterol, 40, pp.381~388 (2005)
- Khuroo MS, "Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4", Aliment Pharmacol Ther, 20, pp.931~938 (2004)
- Jacobson IM, "Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial", Hepatology, 46, pp.971~981 (2007)
- Colin C, "Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature", J Viral Hepat, 8, pp.87~95 (2001)
- Simmonds P, "Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes", Hepatology, 42, pp.962~973 (2005)
- Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Livak KJ, "Allelic discrimination using fluorogenic probes and the 5’ nuclease assay", Genet Anal, 14, pp.143~149 (1999)
- Norušis MJ, "SPSS statistics 17.0: advanced statistical procedures companion" (2009), Prentice Hall
- Devlin B, "A comparison of linkage disequilibrium measures for fine-scale mapping", Genomics, 29, pp.311~322 (1995)
- Peakall R, "GenAlEx 6: genetic analysis in Excel. Population genetic software for teaching and research", Mol Ecol Notes, 6, pp.288~295 (2006)
- Peakall R, "GenAlEx 6.5: genetic analysis in Excel. Population genetic software for teaching and research: an update", Bioinformatics, 28, pp.2537~2539 (2012)
- Szabo G, "Hepatitis C and innate immunity: recent advances", Clin Liver Dis, 12, pp.675~692 (2008)
- Cerny A, "Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence", Hepatology, 30, pp.595~601 (1999)
- Neumann AU, "Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy", Science, 282, pp.103~107 (1998)
- Yamamoto S, "Structure of the osteopontin gene and its promoter", Ann N Y Acad Sci, 760, pp.44~58 (1995)